Viru-chord Liquid
NDC Package 64578-0128-1
Package Information
Viru-chord (belladonna, cinchona officinalis, echinacea (angustifolia), gelsemium sempervirens, glandula suprarenalis suis, glycyrrhiza glabra, hepar suis, hydrastis canadensis, illicium anisatum, influenzinum, lachesis mutus, lappa major, magnesia phosphorica, morbillinum, myrrha, nasturtium aquaticum, nux vomica, paloondo, pyridoxinum hydrochloricum, riboflavinum, sambucus nigra, scutellaria lateriflora, thiaminum hydrochloricum, thyroidinum (bovine)) liquids is classified as a
- allergens - [cs]
- allergens - [cs]
- analogs/derivatives - [chemical/ingredient]
- calculi dissolution agent - [epc] (established pharmacologic class)
- cell-mediated immunity - [pe] (physiologic effect)
- dietary proteins - [cs]
- increased histamine release - [pe] (physiologic effect)
- increased igg production - [pe] (physiologic effect)
- increased large intestinal motility - [pe] (physiologic effect)
- inhibition large intestine fluid/electrolyte absorption - [pe] (physiologic effect)
- inhibition small intestine fluid/electrolyte absorption - [pe] (physiologic effect)
- magnesium ion exchange activity - [moa] (mechanism of action)
- non-standardized food allergenic extract - [epc] (established pharmacologic class)
- non-standardized plant allergenic extract - [epc] (established pharmacologic class)
- osmotic activity - [moa] (mechanism of action)
- osmotic laxative - [epc] (established pharmacologic class)
- plant proteins - [cs]
- seed storage proteins - [cs]
- stimulation large intestine fluid/electrolyte secretion - [pe] (physiologic effect)
- vitamin b 6 - [chemical/ingredient]
- vitamin b6 analog - [epc] (established pharmacologic class)
Identification & Billing
Clinical Specifications
- ARCTIUM LAPPA ROOT 4 [hp_X]/mL
- ATROPA BELLADONNA 12 [hp_X]/mL
- CINCHONA OFFICINALIS BARK 12 [hp_X]/mL
- ECHINACEA ANGUSTIFOLIA 4 [hp_X]/mL
- GELSEMIUM SEMPERVIRENS ROOT 6 [hp_X]/mL
- GLYCYRRHIZA GLABRA 4 [hp_X]/mL
- GOLDENSEAL 5 [hp_X]/mL
- INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) HEMAGGLUTININ ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) 30 [hp_X]/mL
- INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) NEURAMINIDASE ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) 30 [hp_X]/mL
- INFLUENZA A VIRUS A/SOUTH AUSTRALIA/55/2014 (H3N2) HEMAGGLUTININ ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) 30 [hp_X]/mL
- INFLUENZA A VIRUS A/SOUTH AUSTRALIA/55/2014 (H3N2) NEURAMINIDASE ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) 30 [hp_X]/mL
- INFLUENZA B VIRUS B/UTAH/9/2014 HEMAGGLUTININ ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) 30 [hp_X]/mL
- INFLUENZA B VIRUS B/UTAH/9/2014 NEURAMINIDASE ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) 30 [hp_X]/mL
- LACHESIS MUTA VENOM 12 [hp_X]/mL
- LARREA TRIDENTATA LEAF 12 [hp_X]/mL
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 12 [hp_X]/mL
- MEASLES VIRUS 30 [hp_X]/mL
- MYRRH 4 [hp_X]/mL
- NASTURTIUM OFFICINALE 6 [hp_X]/mL
- PORK LIVER 9 [hp_X]/mL
- PYRIDOXINE HYDROCHLORIDE 12 [hp_X]/mL
- RIBOFLAVIN 12 [hp_X]/mL
- SAMBUCUS NIGRA FLOWERING TOP 4 [hp_X]/mL
- SCUTELLARIA LATERIFLORA 6 [hp_X]/mL
- STAR ANISE 12 [hp_X]/mL
- STRYCHNOS NUX-VOMICA SEED 12 [hp_X]/mL
- SUS SCROFA ADRENAL GLAND 9 [hp_X]/mL
- THIAMINE HYDROCHLORIDE 12 [hp_X]/mL
- THYROID, BOVINE 9 [hp_X]/mL
- Allergens - [CS]
- Allergens - [CS]
- Analogs/Derivatives - [Chemical/Ingredient]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Dietary Proteins - [CS]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Increased IgG Production - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Non-Standardized Food Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Non-Standardized Plant Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Plant Proteins - [CS]
- Seed Storage Proteins - [CS]
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
- Vitamin B 6 - [Chemical/Ingredient]
- Vitamin B6 Analog - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 64578 - Energetix Corporation
- 64578-0128 - Viru-chord
- 64578-0128-1 - 59.1 mL in 1 BOTTLE, DROPPER
- 64578-0128 - Viru-chord
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64578-0128-1 identifies a specific commercial package of 59.1 ml in 1 bottle, dropper of Viru-chord, a human over the counter drug labeled by Energetix Corporation. This liquid is formulated for oral use and contains arctium lappa root; atropa belladonna; cinchona officinalis bark; echinacea angustifolia; gelsemium sempervirens root; glycyrrhiza glabra; goldenseal; influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated); influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated); influenza a virus a/south australia/55/2014 (h3n2) hemagglutinin antigen (mdck cell derived, propiolactone inactivated); influenza a virus a/south australia/55/2014 (h3n2) neuraminidase antigen (mdck cell derived, propiolactone inactivated); influenza b virus b/utah/9/2014 hemagglutinin antigen (mdck cell derived, propiolactone inactivated); influenza b virus b/utah/9/2014 neuraminidase antigen (mdck cell derived, propiolactone inactivated); lachesis muta venom; larrea tridentata leaf; magnesium phosphate, dibasic trihydrate; measles virus; myrrh; nasturtium officinale; pork liver; pyridoxine hydrochloride; riboflavin; sambucus nigra flowering top; scutellaria lateriflora; star anise; strychnos nux-vomica seed; sus scrofa adrenal gland; thiamine hydrochloride; thyroid, bovine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Energetix Corporation on June 01, 2016. The current certification is valid through December 31, 2026.
How is this Energetix Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64578012801. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.